What's Happening?
Researchers at St. Jude Children’s Research Hospital have identified the gene-regulatory protein PHIP as a critical vulnerability in cancers driven by SWI/SNF mutations. These mutations, affecting the chromatin-remodeling complex, are present in about
one in four cancers. The study, published in Nature Communications, highlights PHIP as a potential therapeutic target for hard-to-treat cancers, including rhabdoid tumors in children. The research used cell line and patient-derived models to demonstrate how PHIP supports cancer growth by cooperating with SWI/SNF to activate transcription and suppress the opposing NuRD complex.
Why It's Important?
The discovery of PHIP as a dependency in SWI/SNF-mutant cancers opens new avenues for targeted cancer therapies. These findings are particularly significant for pediatric cancers like rhabdoid tumors, which have limited treatment options. By targeting PHIP, researchers hope to develop new treatments that can effectively combat these aggressive cancers. The study also underscores the importance of understanding the molecular mechanisms underlying cancer growth, which can lead to more precise and effective therapies.
